Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) announced that the European Patent Office (EPO) will grant a patent for its RLF-TD011 treatment on February 26, 2025. The patent, titled 'Therapeutic Uses of Oxidizing Hypotonic Acid Solutions,' will protect the company's proprietary hypochlorous acid solutions for treating epidermolysis bullosa (EB) wounds in European markets until 2040.
The treatment has already received orphan drug designation from the FDA, and Relief plans to seek qualified infectious disease product (QIDP) designation. The company recently reported positive results from its investigator-initiated clinical trial for RLF-TD011 and is preparing a pre-IND meeting package for FDA submission. Patent applications are also under review in other major markets, including the United States and China.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) ha annunciato che l'Ufficio Europeo dei Brevetti (EPO) concederà un brevetto per il suo trattamento RLF-TD011 il 26 febbraio 2025. Il brevetto, intitolato 'Usi terapeutici di soluzioni di acido ipotonico ossidante,' proteggerà le soluzioni proprietarie di acido ipocloroso dell'azienda per il trattamento delle wound di epidermolisi bollosa (EB) nei mercati europei fino al 2040.
Il trattamento ha già ricevuto la designazione di farmaco orfano dalla FDA e Relief prevede di richiedere la designazione di prodotto per malattie infettive qualificate (QIDP). L'azienda ha recentemente riportato risultati positivi dal suo studio clinico iniziato da un investigatore per RLF-TD011 e sta preparando un pacchetto per la riunione pre-IND per la submission alla FDA. Le domande di brevetto sono anche in fase di revisione in altri mercati importanti, tra cui gli Stati Uniti e la Cina.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) anunció que la Oficina Europea de Patentes (EPO) concederá una patente para su tratamiento RLF-TD011 el 26 de febrero de 2025. La patente, titulada 'Usos terapéuticos de soluciones ácidas hipotónicas oxidantes', protegerá las soluciones de ácido hipocloroso de la empresa para el tratamiento de heridas de epidermólisis bullosa (EB) en los mercados europeos hasta 2040.
El tratamiento ya ha recibido la designación de medicamento huérico por parte de la FDA, y Relief planea solicitar la designación de producto de enfermedad infecciosa calificada (QIDP). La empresa reportó recientemente resultados positivos de su ensayo clínico iniciado por investigadores para RLF-TD011 y está preparando un paquete para la reunión pre-IND para la presentación a la FDA. Las solicitudes de patente también están siendo revisadas en otros mercados importantes, incluidos Estados Unidos y China.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY)는 유럽특허청(EPO)이 2025년 2월 26일 RLF-TD011 치료법에 대한 특허를 부여할 것이라고 발표했습니다. '산화성 저장성 산 수용액의 치료적 용도'라는 제목의 이 특허는 2040년까지 유럽 시장에서 표피박리수포증 (EB) 상처 치료를 위한 회사의 독점적 하이포클로러스산 솔루션을 보호합니다.
이 치료법은 이미 FDA에서 고아약 지정을 받았으며, Relief는 자격 있는 감염병 제품(QIDP) 지정을 요청할 계획입니다. 회사는 RLF-TD011에 대한 연구자 주도 임상 시험에서 긍정적인 결과를 최근 보고했으며, FDA 제출을 위한 사전 IND 회의 패키지를 준비하고 있습니다. 또한 미국과 중국을 포함한 다른 주요 시장에서도 특허 신청이 심사 중입니다.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) a annoncé que l'Office européen des brevets (OEB) délivrera un brevet pour son traitement RLF-TD011 le 26 février 2025. Le brevet, intitulé 'Utilisations thérapeutiques de solutions acides hypotonique oxydantes,' protégera les solutions de l'entreprise à base d'acide hypochloreux pour le traitement des plaies d'épidermolyse bulleuse (EB) sur les marchés européens jusqu'en 2040.
Le traitement a déjà reçu la désignation de médicament orphelin de la FDA et Relief prévoit de demander la désignation de produit pour maladies infectieuses qualifiées (QIDP). L'entreprise a récemment rapporté des résultats positifs issus de son essai clinique initié par un investigateur pour RLF-TD011 et prépare un dossier pour la réunion pré-IND à soumettre à la FDA. Les demandes de brevet sont également en cours d'examen dans d'autres marchés importants, y compris les États-Unis et la Chine.
Relief Therapeutics (SIX:RLF, OTCQB:RLFTF, RLFTY) gab bekannt, dass das Europäische Patentamt (EPO) am 26. Februar 2025 ein Patent für die Behandlung RLF-TD011 erteilen wird. Das Patent mit dem Titel 'Therapeutische Anwendungen von oxidierenden hypotonischen Säurelösungen' wird die hausinternen hypochlorigen Säurelösungen des Unternehmens zum Schutz der Wunden bei epidermolysis bullosa (EB) in den europäischen Märkten bis 2040 schützen.
Die Behandlung hat bereits die Orphan-Drug-Designation von der FDA erhalten, und Relief plant, eine qualifizierte Produktbezeichnung für Infektionskrankheiten (QIDP) zu beantragen. Das Unternehmen hat kürzlich positive Ergebnisse aus seiner klinischen Studie, die von einem Forscher initiiert wurde, für RLF-TD011 berichtet und bereitet ein Vorbereitungs-Paket für das FDA-Vorbesprechungstreffen vor. Patent-Anträge werden auch in anderen wichtigen Märkten, einschließlich der Vereinigten Staaten und China, überprüft.
- Patent protection secured in Europe until 2040
- Existing FDA orphan drug designation
- Positive clinical trial results reported
- Potential for additional market exclusivity through QIDP designation
- None.
Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment
GENEVA, SWITZERLAND / ACCESS Newswire / February 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the European Patent Office (EPO) has issued a Decision to Grant for its patent application titled "Therapeutic Uses of Oxidizing Hypotonic Acid Solutions."
This patent will protect therapeutic applications of Relief's proprietary, highly pure hypochlorous acid solutions, including its investigational drug RLF‑TD011 for the treatment of wounds caused by epidermolysis bullosa (EB) in key European countries.
The EPO is expected to formally issue the patent on February 26, 2025, under patent number EP 3993811. The patent will remain in effect until 2040, as anticipated by the Notice of Allowance received in October 2024. Corresponding patent applications are under review in other major markets, including the United States and China.
RLF-TD011 has previously received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of EB. The Company also intends to seek qualified infectious disease product (QIDP) designation from the FDA. These designations would provide potential incentives such as market exclusivity upon approval.
Relief continues to advance the development of its lead program and recently reported positive results from its investigator-initiated clinical trial evaluating RLF-TD011 for the treatment of EB. The Company is currently preparing a pre-IND meeting package for submission to the FDA to finalize the remaining clinical development and regulatory strategy for RLF-TD011.
ABOUT RLF-TD011
RLF-TD011 is a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO™ technology. With strong antimicrobial properties, RLF-TD011 is a sprayable, self-administered solution for targeted wound application while avoiding skin contact and cross-contamination. RLF-TD011 has demonstrated efficacy in accelerating wound closure and reducing infections in certain clinical trials on non-EB wounds. In an investigator-initiated trial (NCT05533866), RLF-TD011 has also shown promising results in infection control and wound healing in EB patients with the most severe forms of the disease. RLF-TD011 aims to address unmet needs in EB care by efficiently controlling infection and inflammation while reducing antibiotic use and easing the intensive, time-consuming wound care routine required by current treatments.
ABOUT EPIDERMOLYSIS BULLOSA
Epidermolysis bullosa (EB) is a group of rare, inherited connective tissue disorders characterized by extreme skin fragility, leading to blistering and wounds from minor friction or injury. In severe cases, blisters can develop into chronic wounds or form in internal organs such as the mouth or esophagus, leading to painful wounds, recurrent infections, and a deeply impacted quality of life. EB is classified into several major inherited subtypes, each defined by the depth of blister formation within the skin's layers: epidermolysis bullosa simplex (EBS), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS). Treatment is intensive and includes wound care, infection prevention, and pain management. Approximately 500,000 individuals worldwide are affected by EB.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief's portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.
CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
When will Relief Therapeutics' RLF-TD011 patent be granted in Europe?
How long will RLFTY's European patent protection last for RLF-TD011?
What designations has Relief Therapeutics (RLFTY) received for RLF-TD011?
What is the current development status of Relief Therapeutics' RLF-TD011?
In which markets is Relief Therapeutics seeking patent protection for RLF-TD011?
